IGF-I Antibody (AT6F8): sc-517407

IGF-I Antibody (AT6F8) is a mouse monoclonal IgG2b antibody that detects insulin-like growth factor I (IGF-I) in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). IGF-I is a crucial peptide that plays a significant role in various physiological processes, including the stimulation of vascular smooth muscle cell growth and the regulation of renal function, growth, and tissue repair. Notably, IGF-I is also essential for bone formation and resorption, highlighting its importance in maintaining skeletal health. The activity of IGF-I is intricately modulated by a family of six circulating IGF-binding proteins (IGFBP1-6), which help regulate IGF-I availability and biological effects. Furthermore, IGF-I interacts with IGF-IR receptor, which is structurally similar to the insulin receptor, consisting of two extracellular alpha chains and two beta chains that transmit signals within the cell. IGF-IR receptor′s proper functioning is vital for mediating the diverse effects of IGF-I, including IGF-I influence on insulin sensitivity and glucose uptake, making IGF-I a key player in metabolic regulation. Anti-IGF-I antibody (AT6F8) is an invaluable tool for researchers investigating the multifaceted roles of IGF-I in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGF-I Antibody (AT6F8) References:

1. Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid.  |  Ohtsuru, A., et al. 2000. Endocr J. 47 Suppl: S41-4. PMID: 10890181
2. Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats.  |  Fedele, MJ., et al. 2001. J Appl Physiol (1985). 90: 1166-73; discussion 1165. PMID: 11181633
3. Insulin-like growth factor-binding protein (IGF-BP) inhibition of granulosa cell function: effect on cyclic adenosine 3',5'-monophosphate, deoxyribonucleic acid synthesis, and comparison with the effect of an IGF-I antibody.  |  Bicsak, TA., et al. 1990. Endocrinology. 126: 2184-9. PMID: 1690638
4. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.  |  Chen, H., et al. 2014. J Clin Endocrinol Metab. 99: E1635-40. PMID: 24878056
5. A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.  |  Zhao, Q., et al. 2015. Int J Cancer. 137: 2243-52. PMID: 25924852
6. Insulin-like growth factor-I (IGF-I) and IGF-I receptor in human testis: an immunohistochemical study.  |  Vannelli, BG., et al. 1988. Fertil Steril. 49: 666-9. PMID: 2965033
7. The binding sites of insulin-like growth factor I (IGF I) to type I IGF receptor and to a monoclonal antibody. Mapping by chemical modification of tyrosine residues.  |  Maly, P. and Lüthi, C. 1988. J Biol Chem. 263: 7068-72. PMID: 2966799
8. Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts.  |  Flier, JS., et al. 1986. Proc Natl Acad Sci U S A. 83: 664-8. PMID: 3003744
9. IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis.  |  Yang, K., et al. 2024. J Exp Clin Cancer Res. 43: 46. PMID: 38342894
10. Potentiation of insulin-like growth factor-I (IGF-I) activity by an antibody: supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins.  |  Stewart, CE., et al. 1993. Endocrinology. 133: 1462-5. PMID: 7689959

The preferred IGF-I antibody is IGF-I Antibody (W18): sc-74116.